Exsure, a biotech startup focused on transforming cancer treatment, has raised Rs 3 crore in a seed funding round led by Unicorn India Ventures. The funds will be used to advance the company’s exosome-based drug delivery platform, finalize a non-clinical study, and support its global expansion plans. Exsure also plans to enhance its in-house manufactured R&D products, including its flagship offerings—Exosure, Leucosure, PlantExosure, and Dr. Berries.
Founded in 2021 by Swastika Paul and Abhishek Dutta, Exsure is on a mission to mitigate the side effects and toxicity commonly associated with anti-cancer drugs. By using its patented exosomal drug delivery system, Exsure aims to specifically target cancer cells and cancer stem cells. This innovative technology seeks to minimize the harmful effects of chemotherapy while reducing the risk of cancer relapse, ultimately enhancing the quality of life for patients.
In the past year, Exsure has achieved significant milestones. The company initiated a non-clinical study in India in partnership with a Contract Research Organization (CRO) and completed preclinical studies using its proprietary platform. Exsure also launched its first set of in-house manufactured products and forged collaborations with key partners across India.
The Indian biotechnology market is projected to reach $150 billion by 2025 and could grow to $270–300 billion by 2030, presenting a significant opportunity for startups like Exsure. In line with its growth, Exsure reported fivefold revenue growth in the last fiscal year and is on track to service more than 50 clients this year with its R&D products, such as Exosure (a 3-in-1 exosome isolation reagent), Leucosure (PBMC isolation reagent), and PlantExosure (India’s first plant exosome isolation reagent).
Furthermore, Exsure has been selected for the prestigious OIST Innovation Accelerator Program in Japan, an important step toward expanding its business and conducting clinical trials globally. With this new funding and recognition, Exsure is poised to make a major impact in the biotechnology field, especially in the fight against cancer.
